O. Clyde Hutchinson, David R. Collingridge, Henryk Barthel, Pat. M. Price and Eric O. Aboagye Pages 931 - 944 ( 14 )
Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.
Pharmacodynamics,Radiolabelled,Anticancer Drugs,11C-methyl-choline,ligand-receptor,Positron Emission Tomography (PET)
, , , , CRC PET Oncology Group, Section of Cancer Therapeutics, Imperial College School of Medicine, MRCCyclotron Unit, Hammersmith Hospital, Du Cane Road, London W12 0NN